Blog
RSS FeedPosted by Michael Wonder on 09 Oct 2019
Health Canada approves Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry ...
Posted by Michael Wonder on 01 Oct 2019
Symbicort Turbuhaler now approved by Health Canada for use in mild persistent, moderate, or severe asthma
30 September 2019 - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort Turbuhaler (budesonide/formoterol) ...
Posted by Michael Wonder on 30 Sep 2019
Health Canada approves Dupixent as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
27 September 2019 - Dupixent can significantly reduce the constant itch and improve the skin's overall condition. ...
Posted by Michael Wonder on 28 Sep 2019
Health Canada approves Tecentriq in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer
27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that ...
Posted by Michael Wonder on 17 Sep 2019
I'm not in ...some Third World place': bladder cancer patients face ongoing scarcity of life-saving drug
16 September 2019 - Canada's only supplier, Merck, is now projecting BCG shortage will last until December 2020. ...
Posted by Michael Wonder on 11 Sep 2019
Canada OKs Celltrion's biosimilar
10 September 2019 - Celltrion said that Health Canada has given the go-ahead for Herzuma (trastuzumab), an anticancer antibody biosimilar, ...
Posted by Michael Wonder on 04 Sep 2019
Health Canada updates its biosimilar fact sheet
4 September 2019 - Health Canada recently updated its fact sheet on biosimilars, including new or clarified information about key ...
Posted by Michael Wonder on 29 Aug 2019
‘Nobody can afford this’: family left helpless after Health Canada approves official version of prescription eye drops
28 August 2019 - From the time she was diagnosed with an ultra-rare metabolic disorder as a toddler, Olivia Little ...
Posted by Michael Wonder on 14 Aug 2019
Health Canada approves Tecentriq (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer
13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung ...
Posted by Michael Wonder on 01 Aug 2019
Shortages feared as U.S. looks to Canada for cheaper prescription drugs
31 July 2019 - Canada 'will ensure there are no adverse effects on the supply or cost of prescription drugs,' says ...
Posted by Michael Wonder on 31 Jul 2019
Health Canada approves Vitrakvi (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion ...
Posted by Michael Wonder on 29 Jul 2019
Platelet rich plasma treatment is not classified as a drug, Health Canada says
27 July 2019 - Agency clarifies its position on controversial treatment made popular by superstar athletes. ...
Posted by Michael Wonder on 26 Jul 2019
Federal health minister announces new treatment options for children
25 July 2019 - Health Minister Ginette Petitpas Taylor made the announcement at Health Sciences North in Sudbury on Thursday. ...
Posted by Michael Wonder on 24 Jul 2019
Alnylam launches Onpattro (patisiran) for the treatment of polyneuropathy in hATTR amyloidosis, the first-ever RNAi therapeutic approved in Canada
23 July 2019 - Onpattro is the only treatment that demonstrated improvement, relative to baseline, in both polyneuropathy and quality ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...